Drug Rationing For Seniors Begins – American Spectator
.
.
Buried beneath the avalanche of recent news reports about the latest Obamacare-mandated funding cuts to the Medicare Advantage (MA) program is a related but far more disturbing story – the Centers for Medicare and Medicaid Services (CMS) has taken a major step toward rationing medications to the elderly. Since passage of the Medicare Modernization Act of 2003, seniors enrolled in the Medicare prescription drug program have been guaranteed access to “all or substantially all” of the drugs in several classes of pharmaceuticals. President Obama’s health care bureaucrats, however, have proposed removing three of these classes from the “protected” list.
Buried beneath the avalanche of recent news reports about the latest Obamacare-mandated funding cuts to the Medicare Advantage (MA) program is a related but far more disturbing story – the Centers for Medicare and Medicaid Services (CMS) has taken a major step toward rationing medications to the elderly. Since passage of the Medicare Modernization Act of 2003, seniors enrolled in the Medicare prescription drug program have been guaranteed access to “all or substantially all” of the drugs in several classes of pharmaceuticals. President Obama’s health care bureaucrats, however, have proposed removing three of these classes from the “protected” list.
The New York Times
reports, “The administration’s proposal would remove the protected
status from... immunosuppressant drugs used in transplant patients,
antidepressants and antipsychotic medicines.” Yes, you read that
correctly. These are drugs used to facilitate organ transplants and
treat patients suffering with mental illness. The Times names a few of
the medicines in question: “They include many well-known drugs, such as
Wellbutrin, Paxil and Prozac to treat depression, and Abilify and
Seroquel to treat schizophrenia.” There can be little doubt that the
next step CMS plans to take will involve a decision not to cover the
most expensive of these medications at all.
This is why CMS represents
this as a cost-saving measure. But the amount of money these changes
will save is virtually nothing by Medicare standards. Moreover, as
Yevgeny Feyman writes in Forbes, “The likely reduction in therapeutic
choices could result in higher health care costs in other parts of the
program, like Part A (for hospital care) or Part B (for physician
services).” Further undermining the CMS cost-saving claim is that, due
to the very market features that make it unpopular with Beltway
bureaucrats, the Medicare prescription drug program may be the only
federal entitlement in history whose costs have come in below its
initial CBO projections.
Nonetheless, the Obama
administration didn’t lose its affinity for health care rationing when
Donald Berwick was forced out of CMS. Rationing is as much about control
as it is about money. And this is where the nexus between the CMS drug
proposal and Obamacare’s MA cuts can be found. Medicare’s prescription
drug benefits are administered only through Medicare Advantage, and the
President as well as his bureaucratic accomplices have been gunning for
MA since Obama’s brief pit stop in the Senate. MA introduced private
competition and patient choice into Medicare. That cannot be tolerated.
Medicare must be wholly returned to their fiscally inept control.
Predictably, the CMS
proposal has produced bipartisan protests. As the Times further reports,
“Republican and Democratic members of the Senate Finance Committee
warned that the proposal could ‘diminish access to needed medication’
without saving much money.” On February 19, House Energy and Commerce
Committee Chairman Fred Upton, House Ways and Means Committee Chairman
Dave Camp and Senate Finance ranking member Orrin Hatch wrote to HHS
Secretary Kathleen Sebelius and CMS Administrator Marilyn Tavenner thus:
“As authors of Medicare’s successful prescription drug program... We
are strongly opposed to this proposed regulation.”
The following day, the CMS
head received another protest letter from a surprisingly diverse
coalition of more than 200 groups, including the AIDS Alliance, the
National Kidney Foundation, the U.S. Chamber of Commerce, the
Association of Community Cancer Centers, the Lupus Foundation of
America, the Pharmaceutical Research & Manufacturers of America, the
United Way, various hospitals, physician associations, insurance
companies and pharmacy chains. The letter warns Tavenner that the rule
makes “unnecessary changes to programs that are already extraordinarily
effective” and that it “will impede beneficiaries’ access to affordable
health plans and medicines.”
Even some left-leaning
media outlets are uncomfortable with the Obama administration’s
rationing policy. In the Huffington Post, Professor Kenneth Thorpe of
Emory University’s Rollins School of Public Health, recently pointed out
that the CMS rule “will not only fail to rein in Medicare’s long-term
spending growth, but will inflict severe and unnecessary harm on our
nation’s poor and elderly who are suffering from serious physical and
behavioral illnesses.” Thorpe makes much the same point as does Feyman:
“Restricting access to the medicines patients need to manage depression,
avoid organ transplant rejection, and treat psychosis will drive
healthcare utilization in far more costly ways.”
It’s a little disorienting
to find such an objective view in a publication that normally repeats
Obama administration talking points verbatim, but there it is.
Presumably, this departure from partisanship is an indication of just
how far CMS has over-reached this time. Most Americans regard health
care rationing as repugnant and unnecessary, and we look on it with even
less favor when it is imposed on the elderly. As Professor Thorpe
writes, “That’s a betrayal of Medicare’s promise of access to care for
our most vulnerable, older Americans.” Well said.
No comments:
Post a Comment